FDA Inspection 1152494 — Agios Pharmaceuticals, INC.

Agios Pharmaceuticals, INC. — FEI 3012469070

The FDA completed an inspection of Agios Pharmaceuticals, INC. on Sep 16, 2021 in Cambridge, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI)
End Date
Sep 16, 2021
Fiscal Year
2021
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Cambridge, MA (United States)

Additional Details

Sponsor, Contract Research Organization

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.